D.E. Shaw & Co’s Orexigen Therapeutics OREX Stock Holding History
Bought
Maintained
Sold
Other funds holding OREX
D.E. Shaw & Co's OREX Position: Q1 2016 in Review
D.E. Shaw & Co sold out of Orexigen Therapeutics (OREX) in Q1 2016, closing a stake of 2,229 shares — an estimated $38K sold.
D.E. Shaw & Co first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $8.72M in Q4 2013. 105 funds tracked by Wall St. Rank hold OREX as of Q1 2016.
- D.E. Shaw & Co reported no remaining Orexigen Therapeutics position as of Q1 2016 after selling out during the quarter.
- D.E. Shaw & Co sold 2,229 Orexigen Therapeutics shares in Q1 2016, an estimated $38K.
- D.E. Shaw & Co first reported a position in Orexigen Therapeutics in Q2 2013 and held it in 11 quarters.
- D.E. Shaw & Co's Orexigen Therapeutics position peaked at $8.72M in Q4 2013.
- 105 funds tracked by Wall St. Rank held Orexigen Therapeutics as of Q1 2016.
Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.